Poïesis Therapeutics is a biotechnology start-up focused on sourcing and in-licensing innovative late stage therapeutics and diagnostics from human biomedical research and developing them to address unmet needs in the veterinary market for companion animals – horses, dogs and cats.
Our mission statement adheres to the “one health” concept, reflective of the inherent synergies between animal and human medicine.
Developing new medicines to address unmet needs in animal health.
Developing new veterinary diagnostics to identify disorders in dogs, cats and horses.
Corporate Social Responsibility
Poïesis contributes a percentage of its profits to chosen charities which are making a difference for humans and animals.
Following on its move from London to San Diego, California, Poïesis has opened its Seed Round of financing seeking to raise $5 million to complete in-licensing and initiate clinical development of its therapeutic and diagnostic pipeline in several indications in dogs,...read more
By Mary Guiden, Communications Coordinator, Coleman Cornelius, Director of Communications and Dell Rae Ciaravola, Senior Media and Community Relations Coordinator The backdrop of storm clouds added to the atmosphere of import as Colorado State University leaders and...read more
By Joseph Harvey, 20 April 2017. So far, 2017 has said farewell to Merial and seen the purchase of Nexvet Biopharma – two very different companies in the animal health space. Animal Pharm editor Joseph Harvey takes a closer look at these two transactions and their...read more
Companies focused on developing treatments for dogs, cats, and horses are bringing a diverse array of products to the pet medicine market. By Jenny Rood | October 1, 2016. Around Christmas 2010, University of Minnesota researcher Mark Suckow received terrible news:...read more
Zoetis to Acquire Nexvet Biopharma, an Innovator in Monoclonal Antibody Therapies for Companion Animals
Purchase price of US$6.72 per share, or approximately US$85 million in aggregate Acquisition to strengthen Zoetis’ pipeline in companion animal therapeutics for chronic pain, a global area estimated at US$400 million annually 1 PARSIPPANY, N.J. & TULLAMORE,...read more
By Mary Guiden, Communications Coordinator, CSU. Through its clinical trials for animal patients, Colorado State University helped prove the usefulness of the first drug approved by the FDA for treatment of canine lymphoma, a breakthrough in veterinary oncology...read more
By Cathy Yarbrough, Contributing Editor For Aratana Therapeutics, 2016 was a banner year. The biotech company, founded in 2010, achieved FDA approvals for three of its 10 pipeline drugs. Last year the Kansas City-based company also forged a global partnership...read more
Provides Hope for Humans When Krista DeZerega-Thomson got the dreaded news that Rohan, the family’s beloved Labrador retriever, had cancer, she was devastated. He had metastatic melanoma—an aggressive form that affects dogs and humans—and was given only two months to...read more
Fred, a 6-year-old male shepherd cross, was diagnosed by his referring veterinarian with cancer in his left forelimb in April 2016. Due to preexisting orthopedic issues, he was not a candidate for the traditional amputation and chemotherapy treatment. Faced with only...read more
Poïesis Therapeutics Successfully Completes CONNECT Internationally Acclaimed Springboard Accelerator Program SAN DIEGO, July 18, 2017 -- Poïesis Therapeutics, a biotechnology start-up in the pet health industry, is pleased to announce that the company has...read more
Company Chosen to Compete at Group's Annual Holiday Dinner Following Lengthy Selection Process From 120 Applicants SAN DIEGO, December 1, 2016 -- Poïesis Therapeutics, a biotechnology start-up in the pet health industry, is pleased to announce that the company...read more